Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Scroll Up
Scroll Down

Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Bookmark and Share

Tecan Group Ltd.

Bioassays designed to measure antibody-dependent cell-mediated cytotoxicity (ADCC) are particularly useful when looking to understand and characterize mechanism of action, and to quantify biologic potency and stability of target compounds during discovery and development.

However, the labor and skill required to isolate primary natural killer cells for ADCC or to maintain alternative cell lines in culture with any level of reproducibility remains problematic, with high costs in consumable reagents and in purchasing and maintaining basic equipment.

Promega has developed reporter bioassays that use activation of gene transcription through NFAT (nuclear factor of activated T-cells) as an earlier measure of ADCC. The bioassays use frozen, thaw-and-use effector and target cells and eliminates the need for cell culture maintenance. The use of frozen cells also decreases assay variability. 

The ADCC Reporter Bioassay requires six-hour incubation with cells and antibody for optimal NFAT activation and luciferase expression to occur.The Tecan Infinite® 200 PRO, equipped with an external module that enables simultaneous adjustment of CO2 and O2, provides an alternative method enabling scientists without access to a cell culture facility to easily perform the bioluminescent reporter bioassay.

Further Information


Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!